Accrete Health Invests in ReveloHealth for Contract Performance

Accrete Health Partners has taken a stake in ReveloHealth, a software platform that helps healthcare systems catch underpayments and enforce contract terms with commercial insurers. The investment — announced Wednesday with undisclosed terms — will fund expansion of ReveloHealth's AI-powered tools for contract performance management and reimbursement accuracy, according to the company's statement.

The deal lands as hospitals face mounting pressure to recover revenue lost to payment errors and contract interpretation disputes — a problem that costs U.S. health systems an estimated $262 billion annually in denied claims and underpayments, per the American Hospital Association. ReveloHealth's pitch: automate the grunt work of auditing millions of claims against complex payer contracts, flagging discrepancies before they compound.

"We've spent years building relationships with health systems that trust us to find money they didn't know they were missing," said ReveloHealth CEO Alex Marker in the announcement. "This partnership accelerates our ability to serve more organizations while deepening the analytical capabilities that make contract performance measurable."

Accrete Health, a Dallas-based private equity shop focused on healthcare software and services, sees the investment as part of a broader thesis around revenue cycle optimization. The firm has backed similar platforms targeting the space between what hospitals are owed and what they actually collect — a gap that's widened as payer-provider contracts grow more complex and commercial denial rates climb.

Healthcare reimbursement operates on a premise that breaks down in practice: negotiate a contract with an insurer, deliver care, get paid according to the terms. Except the terms are rarely simple. Contracts can run hundreds of pages, with carve-outs for specific procedures, seasonal rate adjustments, and quality-based bonuses that shift quarterly. Claims get adjudicated by automated systems that may or may not interpret those terms the same way the provider does.

The result? Chronic underpayment that often goes unnoticed until someone manually audits a sample of claims — if they audit at all. A 2023 survey by the Healthcare Financial Management Association found that 63% of hospitals lack a systematic process for verifying that commercial payers are following contracted rates. Most rely on retrospective reviews conducted months after the fact, when recovery becomes a negotiation rather than a correction.

ReveloHealth positions itself as the continuous audit layer. The platform ingests payer contracts and claims data, running each remittance through a rules engine that flags discrepancies in real time. It's not chasing denied claims — it's identifying claims that were paid, just not at the right amount.

That distinction matters. Denials trigger appeals processes that most revenue cycle teams are built to handle. Underpayments slip through because the check arrives, the system marks it paid, and no one questions whether the contracted rate was applied correctly. ReveloHealth's software treats every payment as provisional until verified.

The platform operates in three phases: contract digitization, payment verification, and recovery workflow. First, ReveloHealth's team converts multi-hundred-page payer contracts into machine-readable logic — essentially translating legalese into an auditable rules database. That's the labor-intensive part, and it's where most homegrown attempts at contract modeling fall apart.

Once the contract is digitized, the software monitors every claim adjudication, comparing the payer's remittance to what the contract specifies. When there's a gap, the platform generates a discrepancy report with the clause reference and dollar variance. Revenue cycle teams get a dashboard of potential recovery targets, ranked by financial impact.

The third phase is where things get harder: actually getting the money. ReveloHealth provides the documentation package for appeals, but it's still on the hospital to negotiate with the payer. Some discrepancies get resolved quickly — a coding error, a rate lookup mistake. Others become protracted disputes over contract interpretation, especially when the language is ambiguous.

ReveloHealth claims its customers recover an average of 1.2% of net patient revenue annually through its platform — a modest-sounding figure that translates to millions for mid-sized systems. But the company won't disclose how much of identified underpayment actually gets collected, which is where vendor promises typically diverge from customer experience.

The platform's newest capabilities lean on machine learning to surface patterns that rules-based systems miss. For instance: a payer that consistently underpays a specific CPT code by 8% across multiple claims, but not enough to trigger an obvious error. Or seasonal drift in how quality bonuses are calculated, suggesting the payer's adjudication logic changed without formal notice.

Accrete Health's investment thesis centers on healthcare software companies that solve high-pain, low-visibility problems — the kind that CFOs care about but don't generate press releases when fixed. Contract performance management fits squarely in that category. It's not flashy, but it's financially material.

The firm's portfolio includes revenue cycle analytics, prior authorization automation, and payer-provider data exchange platforms — all tools designed to reduce friction in the money movement between insurers and providers. ReveloHealth extends that portfolio into post-adjudication verification, closing a loop that most of Accrete's other investments don't touch.

"ReveloHealth sits at the intersection of contract complexity and payment automation — two trends that aren't reversing," said Accrete Health Managing Director Sarah Kampman in the announcement. The firm sees increasing contract sophistication (value-based care, episode-based pricing, quality incentives) colliding with payer automation that hasn't caught up, creating structural opportunities for software that can bridge the gap.

Accrete's support will fund expansion into integrated delivery networks and academic medical centers, segments where contract volumes and complexity make manual auditing impractical. ReveloHealth currently serves primarily mid-sized health systems; scaling up-market requires more robust integrations with ERP systems like Epic and Oracle Health, plus account management teams capable of navigating multi-facility contracting hierarchies.

The investment also backs product development around predictive analytics — tools that forecast likely underpayment risk at the time of contract negotiation, before the first claim is filed. If a payer's proposed rate schedule shows historical patterns of adjudication disputes, the software would flag it during the contracting phase rather than months later during reconciliation.

ReveloHealth plans to double its client base within 18 months, according to company leadership. The firm currently works with 47 health systems across 18 states, concentrating in the Southeast and Midwest. Expansion targets include California and the Northeast, where commercial payer mix and contract complexity create richer recovery opportunities.

Sales cycles average nine months — long even by healthcare software standards — because implementation requires legal review of vendor access to payer contracts, plus IT integration with claims management systems. Accrete's backing funds a larger sales team and faster onboarding infrastructure, aiming to compress that timeline.

ReveloHealth operates in a fragmented landscape. Competitors range from Big Four consulting arms that offer contract modeling as part of broader revenue cycle engagements, to niche software vendors focused on specific underpayment categories (like surgical implant cost recovery or outlier payment audits), to in-house teams at large systems building proprietary tools.

No single player dominates contract performance management the way Epic dominates EHR or Change Healthcare dominates claims clearinghouse. That fragmentation reflects the complexity: every health system's contracting structure is different, and most underpayment problems are idiosyncratic rather than universal.

Notable competitors include MD Clarity, which focuses on contract modeling and rate transparency, and Revint Solutions, which targets post-payment audits. Both have raised growth capital in recent years. The category has attracted interest from larger revenue cycle vendors like R1 RCM and Optum, which have acquired or built internal tools rather than partnering with point solutions.

The risk for standalone vendors like ReveloHealth is commoditization — if contract verification becomes table stakes functionality in broader RCM platforms, hospitals may opt for bundled offerings rather than best-of-breed tools. That's the strategic logic behind Accrete's investment: scale fast enough to become the de facto standard before larger platforms catch up.

One underexplored dynamic: how payers respond when every claim gets audited in real time. Some CFOs worry that aggressive contract enforcement could sour payer relationships, particularly in markets where a single insurer controls 40%+ of commercial volume. There's also the possibility that payers tighten adjudication logic once they realize systematic auditing is underway, making future underpayments harder to identify.

ReveloHealth's counterargument is that better contract adherence benefits both sides — fewer disputes, faster resolution, clearer terms in future negotiations. But that assumes good faith on both ends, which isn't always present when margins are tight and every basis point matters.

While ReveloHealth doesn't disclose financials, industry benchmarks suggest the economic model works like this: customers typically pay a percentage of recovered revenue (20-35%) or a flat SaaS fee plus success-based component. Implementation costs run $150K-$400K depending on contract volume and system complexity. Payback periods average 8-14 months, per conversations with CFOs at two mid-sized health systems using the platform.

The challenge with performance-based pricing is that it ties revenue to the customer's willingness to pursue appeals. Some hospitals identify $2 million in underpayment but only recover $800K because they don't want to antagonize a key payer. ReveloHealth gets paid on recovery, not identification, which aligns incentives but also caps revenue in risk-averse markets.

Larger systems show lower recovery rates not because the software works worse, but because they face more complex payer dynamics and are more selective about which disputes to escalate. A 500-bed community hospital might chase every $5K discrepancy; a 12-hospital academic system picks its battles.

The company claims its software has identified over $340 million in underpayments since inception, though it doesn't specify how much has actually been collected. That gap between identified and recovered is where customer expectations often collide with vendor marketing.

The immediate roadmap focuses on faster contract digitization (currently the bottleneck in onboarding) and predictive modeling that forecasts payer behavior before claims are filed. Longer-term, ReveloHealth sees opportunity in reverse workflows: helping payers identify their own overpayments before providers do, positioning the platform as neutral infrastructure rather than adversarial audit tool.

There's also nascent interest in applying the same contract verification logic to government payers — Medicare Advantage and Medicaid managed care — where underpayment patterns exist but recovery processes are more constrained. ReveloHealth hasn't committed to that expansion publicly, but multiple health system CFOs have asked for it.

The broader question is whether contract performance management remains a standalone category or gets absorbed into larger platforms. Accrete's bet is that complexity sustains specialization — that hospitals will continue to pay for best-in-class tools rather than accept good-enough functionality bundled into enterprise RCM suites.

If that thesis holds, ReveloHealth has runway. If not, the endgame might be an acquisition by one of those enterprise vendors, which would still make the investment work for Accrete. Either way, the underlying problem isn't going away: hospitals are owed money they're not collecting, and someone's going to build the infrastructure to close that gap.

For now, the investment signals that at least one PE firm believes the contract performance opportunity is big enough to justify scaled investment — and that ReveloHealth has enough traction to execute. Whether that conviction translates to market dominance or just a solid return depends on how fast the company can onboard customers before larger competitors take the category seriously.

If you're evaluating contract performance software, the diligence conversation should start with three questions ReveloHealth's marketing materials don't emphasize enough:

First: What's your actual recovery rate, not just identification rate? Vendors love to tout total underpayment flagged; customers care about cash collected. Ask for customer references who can speak to how much of identified revenue actually made it back into the bank account.

Second: How do you handle contract interpretation disputes? When the language is ambiguous and the payer disagrees with your reading, what's the escalation process? Does the vendor provide legal support, or is that on the hospital's counsel?

Third: What happens when a payer pushes back on systematic auditing? If your largest commercial partner threatens to walk away from negotiations because you're auditing every claim, does the vendor have a playbook for that scenario, or are you on your own?

Those questions matter more than feature lists or ROI projections, because they surface the operational realities that determine whether contract performance software becomes a revenue driver or an expensive reporting tool.